Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe. Medical uses
Frovatriptan is used in the treatment of migraine. Available forms
It is available as 2.5 mg tablets. Contraindications
Frovatriptan should not be given to patients with:

Ischemic heart disease
Cerebrovascular syndrome
Peripheral vascular disease
Uncontrolled hypertension
Hemiplegic or basilar migraine

Side effects
Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation. Pharmacology
Pharmacodynamics
Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. Pharmacokinetics
Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class. Society and culture
US licensing
Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006. References
External links
Frova (manufacturers website)
Frovatriptan Succinate  (patient information)
FDA labeling
Adult worms have a lifespan of 1–2 years which means that individuals may be infected all their lives as worms die and new worms are acquired.Eggs can survive potentially for 15 years and a single worm may produce 200,000 eggs a day. They maintain their position by swimming against the intestinal flow. Mechanism
Ascaris takes most of its nutrients from the partially digested host food in the intestine. There is some evidence that it can secrete enzyme inhibitors, presumably to protect itself from digestion by the hosts enzymes. Children are often more severely affected. Diagnosis
Most diagnoses are made by identifying the appearance of the worm or eggs in feces. Due to the large quantity of eggs laid, diagnosis can generally be made using only one or two fecal smears. The diagnosis is usually incidental when the host passes a worm in the stool or vomit. The eggs can be seen in a smear of fresh feces examined on a glass slide under a microscope and there are various techniques to concentrate them first or increase their visibility, such as the ether sedimentation method or the Kato technique. The eggs have a characteristic shape: they are oval with a thick, mamillated shell (covered with rounded mounds or lumps), measuring  35–50 micrometer in diameter and 40–70 in length. During pulmonary disease, larvae may be found in fluids aspirated from the lungs. White blood cell counts may demonstrate peripheral eosinophilia; this is common in many parasitic infections and is not specific to ascariasis.